These findings collectively indicate that modulation of the gut microbiota–SCFA–GPR axis plays a pivotal role in alleviating DN-associated renal fibrosis, supporting its potential as a microbiota-targeted therapeutic strategy for improving renal outcomes in DN. Here, ALDH18A1 is linked to renal fibrosis.